RNA Therapeutics CDMO Market Size To Reach USD 40.68 Billion By 2035 At A CAGR Of 9.86% - SNS Insider
Austin, United States, Sept. 11, 2026 (GLOBE NEWSWIRE) -- RNA Therapeutics CDMO Market Size & Growth Analysis:
According to SNS Insider, The RNA Therapeutics CDMO Market
RNA Therapeutics CDMO Market Key Highlights
- Market size, 2025: USD 15.90 Billion Market forecast, 2035: USD 40.68 Billion CAGR: 9.86% from 2026 to 2035 Largest region: North America, approximately 46.00% share in 2025 Fastest-growing region: Asia Pacific, approximately 13.79% CAGR Largest RNA type: mRNA Therapeutics & Vaccines, approximately 48.00% share in 2025 Fastest-growing RNA type: ASO, circRNA & Other RNA Modalities, approximately 11.21% CAGR Largest service type: Clinical Manufacturing, approximately 42.00% share in 2025 Fastest-growing service type: Commercial Manufacturing & Fill-Finish, approximately 12.43% CAGR Largest application: Infectious Diseases, approximately 39.00% share in 2025 Fastest-growing application: Oncology, approximately 11.62% CAGR Largest & fastest-growing end user: Biopharmaceutical Companies, approximately 58.00% share in 2025 and approximately 12.56% CAGR
Market Relevance
The field of RNA-based drug discovery is increasingly relying on external partnerships, since the technical difficulty associated with RNA production, purification, formulation, and storage surpasses the ability of biotech firms to handle these operations internally. Outsourcing enables pharmaceutical firms to save time and leverage technology for the purpose of manufacturing RNA-based drugs.
RNA Therapeutics CDMO Market Overview
The market includes mRNA therapeutics and vaccines in addition to ASO, circRNA, and other RNA modalities that are delivered via clinical and commercial manufacturing and fill-finish solutions for infectious disease, oncology, and other biopharma applications. The mRNA therapeutics and vaccines continue to be the leading modality due to their large number of clinical applications and platform scalability, whereas the ASO and circRNA modalities are growing in market share due to advancements of next generation RNA modalities in terms of stability and specificity. Clinical manufacturing continues to be the largest service offering as a result of an increasing number of RNA pipelines undergoing Phase I-III studies, and commercial manufacturing and fill-finish are rapidly growing as a result of increasing number of RNA therapeutics being commercialized.
Strategic Market Outlook
The opportunities exist in the commercialization of next generation RNA platform technologies, such as circular RNA, self-amplifying RNA, and oligonucleotides. Such technologies are likely to have great potential for the CDMOs that are able to provide end-to-end custom services from discovery to commercialization. The advancements in personalized medicine and therapies will drive the need for specialized manufacturing due to the fact that the next generation RNA technology needs better formulations, testing, and manufacturing.
There are significant constraints in the form of manufacturing complexity and compliance costs. There are complicated issues related to infrastructure, analysis, and quality control involved in the manufacturing of RNA therapeutics. Compliance with GMP in both development and commercial manufacturing is going to increase costs, and there might be complications related to logistics and raw materials.
RNA Therapeutics CDMO Market Regional Analysis
North America contributed around 46.00% to the global revenue in 2025, thereby emerging as the leading region, thanks to biotechnological advancements, clinical trials, and an existing RNA manufacturing base. The U.S. contributed around 94.00% of North American revenue, aided by stringent regulations, significant funding from the private sector, and the presence of a vibrant ecosystem for life sciences and venture capital.
The U.S. RNA Therapeutics CDMO Market was valued at USD 6.87 Billion in 2025 and is expected to reach approximately USD 15.68 Billion by 2035, expanding at a CAGR of 9.60% during 2026-2035.
Europe RNA Therapeutics CDMO Market captured around 28.00% market share globally in 2025, worth USD 4.45 Billion, which is predicted to grow up to USD 10.73 Billion by 2035, growing at a CAGR of 9.20% between 2026 and 2035. Market growth will be attributed to the rise in investments in RNA development and outsourcing service platforms, with Germany, the United Kingdom, France, and Switzerland continuously enhancing their RNA development platforms. Germany captured around 28.00% of total European market revenue in 2025, attributed to an increase in investments in bioprocessing and advanced manufacturing.
Asia-Pacific is estimated to record the fastest CAGR of 13.79% during 2026 and 2035, owing to the rapid growth in the biotechnology industry, rise in healthcare spending, and favorable government policies in China, Japan, South Korea, India, and Singapore. In 2025, China captured around 19.00% market share in the Asia-Pacific region, attributed to the aggressive capacity expansion by regional contract manufacturers for domestic as well as foreign clients.
Middle East & Africa: The region accounted for approximately 3.00% of global market revenue in 2025, with the UAE contributing approximately 4.00% of regional revenue, supported by government biotechnology investment and healthcare system diversification.
Latin America: The region accounted for approximately 4.00% of global market revenue in 2025, with Brazil contributing approximately 3.00% of regional revenue, supported by growing manufacturing activity and biotechnology investment.
Buy the RNA Therapeutics CDMO Market Report with Competitive Analysis and 2035 Forecast:RNA Therapeutics CDMO Market Segment Analysis
By RNA Type: Market share of mRNA Therapeutics & Vaccines is estimated to be around 48.00% in 2025, aided by the widespread adoption of mRNA vaccines and mRNA-based therapies for treating cancer, infectious diseases, and rare diseases. ASO, circRNA & Other RNA Modalities is the fastest growing market segment, estimated to grow at around 11.21% CAGR, due to growing investments in advanced RNA-based therapies.
By Service Type: The market share of Clinical Manufacturing stood at about 42.00% in 2025, attributed to growing numbers of RNA therapeutic products entering into Phase I-III clinical trials. The fastest growing service type is that of Commercial Manufacturing & Fill-Finish, growing at about 12.43% CAGR due to RNA therapeutics entering into commercial production stage.
By Application: The market share of Infectious Diseases was 39.00% in 2025 owing to the rich commercial background of mRNA vaccines. The Oncology segment is the fastest growing application segment and expected to grow at a CAGR of around 11.62%, as RNA-based cancer therapeutics advance through expanding clinical pipelines.
By End User: Biopharmaceutical Companies accounted for around 58.00% market share in 2025 and are also projected to register the fastest growth, at around 12.56% CAGR, as these organizations continue expanding outsourcing relationships to accelerate development and access specialized manufacturing capabilities.
RNA Therapeutics CDMO Market Key Trends
- Increasing outsourcing of RNA process development and GMP manufacturing activities Growing commercialization of mRNA, siRNA, and oligonucleotide therapeutics globally Expansion of large-scale RNA synthesis and lipid nanoparticle manufacturing facilities Rising adoption of AI-enabled manufacturing optimization and digital quality control systems Growing investments in commercial fill-finish infrastructure for RNA-based therapeutics
Competitive Landscape
The RNA Therapeutics CDMO Market includes established contract development and manufacturing organizations, with competition centred on commercial-scale capacity expansion and next-generation RNA platform capability.
In 2026, multiple global CDMOs expanded commercial-scale mRNA and oligonucleotide manufacturing capacity to support late-stage clinical and commercial programs, while several RNA-focused manufacturers invested in AI-enabled process optimization platforms to improve production efficiency and batch consistency. In 2025, industry participants announced new lipid nanoparticle manufacturing facilities supporting next-generation RNA therapeutic development, and strategic partnerships between biotechnology innovators and CDMOs increased to accelerate clinical development and commercialization of RNA-based therapies.
Major key players include
- Lonza Group Catalent, Inc. Thermo Fisher Scientific Inc. WuXi AppTec Samsung Biologics AGC Biologics Recipharm AB CordenPharma International Curia Global, Inc. Evonik Industries AG Aldevron LLC Nitto Avecia Rentschler Biopharma BioNTech SE eTheRNA manufacturing BioSpring GmbH TriLink BioTechnologies GenScript ProBio FUJIFILM Diosynth Biotechnologies Wacker Biotech GmbH
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment